MRK Merck & Company Inc
P/E
115.44
Forward P/E
15.29
Price/Sales
5.39
Beta
0.222
Div Yield
0.0228%
Market Cap
--
Company Analysis
Latest News
CVC Bids $12.4B for Recordati, Merck Lung Cancer Trial Cuts Risk 65%
A consortium led by CVC Capital Partners and Groupe Bruxelles Lambert launched a €10.7 billion ($12.4 billion) cash bid for Italian drugmaker Recordati. The...
Merck's first quarter 2026 revenue grew 5% on KEYTRUDA strength, prompting a raise in full-year guidance.
Merck reported first quarter 2026 sales of $16.3 billion, a 5% increase year-over-year, driven by its Oncology and Animal Health divisions. The company posted...
Merck & Company Inc Q1 2026 Earnings Preview: What Analysts Expect on April 30, 2026
Wall Street expects Merck & Co. to report first-quarter 2026 revenue of approximately $15.90 billion and a consensus EPS loss of $1.51, while the stock...
Big Pharma buys smaller biotechs, boosting sector stocks to fill pipelines
Large pharmaceutical companies are prioritizing strategic bolt-on acquisitions over megadeals. These transactions typically range in the low-single-digit...